Cargando…
Circulating metabolites serve as diagnostic biomarkers for HER2‐positive breast cancer and have predictive value for trastuzumab therapy outcomes
Human epidermal growth factor receptor 2 (HER2)‐positive is a particularly aggressive type of the breast cancer. Trastuzumab‐based therapy is a standard treatment for HER2‐positive breast cancer, but some patients are resistance to the therapy. There are no known diagnostic biomarkers to improve the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842188/ https://www.ncbi.nlm.nih.gov/pubmed/34994982 http://dx.doi.org/10.1002/jcla.24212 |